Bridget Oppong was named deputy director of the Center for Cancer Health Equity at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
Helen M. Piwnica-Worms and Fabrice André will be honored for their contributions to breast cancer research by the San Antonio Breast Cancer Symposium and the American Association for Cancer Research, an SABCS cosponsor, at the 2021 SABCS Dec. 7-10.Â
In mid-October, First Lady Dr. Jill Biden asked to visit the Hollings Cancer Center at the Medical University of South Carolina to help raise awareness of the need for breast cancer screening, education, and treatment—particularly among underserved minority women.
When Susan Love joked that a group of breast cancer advocates in Salt Lake City should march topless to George H. W. Bush’s White House, she didn’t expect to be taken seriously.
Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
Fran Visco never asked for $300 million in breast cancer research funding—she demanded it.
The phase III EMBRACA trial in patients with germline BRCA1/2-positive locally advanced and/or metastatic breast cancer demonstrated superior progression-free survival in patients treated with talazoparib, compared to patients who received physician's choice standard of care chemotherapy.
Novartis announced positive topline results from the global MONALEESA-7 trial, the second phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer.
Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy.
Findings in a single-center study show women with breast cancer who undergo nipple-sparing mastectomy have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed.
